Table 2.
Adjusted hazard ratios for incident osteoporotic fractures in cancer patients compared to non-cancer controls.
| Adjusted HR (95% CI)a | p value | |
|---|---|---|
| All patients with cancer vs. controls | ||
| Cancer cases | 1.10 (1.07–1.14) | <0.0001 |
| Solid vs. controls | ||
| Cancer cases | 1.09 (1.05–1.13) | <0.0001 |
| Haematologic vs. controls | ||
| Cancer cases | 1.20 (1.10–1.31) | <0.0001 |
| Lymphoma vs. controls | ||
| Cancer cases | 1.18 (1.06–1.31) | 0.0018 |
| DLBCL vs. controls | ||
| Cancer cases | 1.38 (1.07–1.77) | 0.012 |
| Indolent lymphoma vs. controls | ||
| Cancer cases | 1.36 (1.17–1.58) | <0.0001 |
| Aggressive lymphoma vs. controls | ||
| Cancer cases | 1.05 (0.90–1.22) | 0.53 |
CI confidence interval, CKD chronic kidney disease, COPD chronic obstructive lung disease, DLBCL diffuse large B cell lymphoma, HR hazard ratio.
aAdjusted for demographic income quintile and rural status, comorbidity burden measured by aggregated clinical group score, CKD, arthritis, dementia, asthma/COPD, cerebrovascular disease, falls, diabetes.